<DOC>
	<DOCNO>NCT02240706</DOCNO>
	<brief_summary>Phase I : To investigate maximum tolerate dose ( MTD ) , safety tolerability , pharmacokinetics , exploratory biomarker efficacy BI 836858 monotherapy patient low intermediate-1 risk myelodysplastic syndrome ( MDS ) symptomatic anemia . Phase II : To investigate safety efficacy BI 836858 plus Best Supportive Care compare Best Supportive Care alone low intermediate-1 risk MDS patient symptomatic anemia without deletion 5q cytogenetic abnormality .</brief_summary>
	<brief_title>Phase I/II Trial Investigate BI 836858 Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Inclusion criterion : 1 . Documented diagnosis MDS accord World Health Organization ( WHO ) criteria meet International Prognostic Scoring System ( IPSS ) classification low intermediate1 risk disease determine microscopic standard cytogenetic analysis bone marrow peripheral complete blood count ( CBC ) refractory amenable eligible approve MDS therapy . 2 . Patient evidence symptomatic anemia accord follow criterion : Phase I : Patients must mean hemoglobin concentration &lt; 10.0 g/dL 2 measurement ( influenced RBC transfusion within 7 day measurement ) receive &lt; 4 unit RBCs within 8 week prior start treatment OR , Phase I/II : Patients must receive &gt; = 4 unit RBCs hemoglobin = 9.0 g/dL within 8 week prior start treatment . 3 . Patient nonresponsive , refractory , intolerant ESAs , ESAs contraindicate unavailable , documented serum erythropoietin level &gt; 500 U/L . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; =2 . 5 . Age &gt; = 18 year . 6 . Written inform consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline local legislation . Exclusion criterion : 1 . Patient IPSS category Int2 highrisk MDS . 2 . Phase II : Patients deletion 5q cytogenetic abnormality . 3 . Treatment within 28 day prior Cycle 1 Day 1 : ) long act erythropoiesis stimulate agent , ii ) long act Granulocyte colonystimulating factor ( GCSF ) , iii ) granulocyte macrophage colony stimulate factor ( GMCSF ) , iv ) 5aza , lenalidomide decitabine , v ) iron chelation within 14 day prior Cycle 1 Day 1 short act erythropoiesis stimulate agent short act GCSF . 4 . Patient previously receive allogeneic bone marrow stem cell transplantation . 5 . Second malignancy currently require active therapy ( except hormonal/antihormonal treatment , e.g . prostate breast cancer ) . 6 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; 2.5 time upper limit normal ( ULN ) . 7 . Prothrombin time ( PT ) &gt; 1.5 x ULN patient therapeutic vitamin K antagonist ( phenprocoumon , warfarin ) . 8 . Bilirubin &gt; 1.5 mg/dL , except Gilbert 's Syndrome hemolysis . 9 . Serum creatinine &gt; 2.0 mg/dL . 10 . Known human immunodeficiency virus ( HIV ) infection active hepatitis B virus hepatitis C virus infection . Patients serological evidence current past hepatitis B exposure exclude unless serological finding clearly due vaccination . 11 . Presence concomitant intercurrent illness , condition opinion Investigator , would compromise safe participation study , e.g . active severe infection , unstable angina pectoris , new onset exacerbation cardiac arrhythmia . 12 . Psychiatric illness social situation opinion Investigator would limit compliance trial requirement . 13 . Patient receive concomitant therapy , opinion Investigator consider relevant evaluation efficacy safety trial drug . 14 . Female patient childbearing potential sexually active unwilling use medically acceptable method contraception trial 6 month last administration BI 836858 , i.e . combination two form effective contraception ( defined hormonal contraception , intrauterine device , condom spermicide , etc. ) . Patients consider childbearing potential unless surgically sterilize hysterectomy , bilateral tubal ligation/salpingectomy postmenopausal least two year . 15 . Male patient partner childbearing potential unwilling use condom combination second effective method contraception ( defined hormonal contraception , intrauterine device , condom spermicide , etc . ) trial 6 month last administration BI 836858 . 16 . Pregnant nursing female patient . 17 . Treatment another investigational agent follow condition : 1 . Within two week ( 4 week biologics ) first administration BI 836858 , halflife previous product know , within 5 time halflife , whichever longer . 2 . Patient persistent toxicity prior MDS therapy determine relevant Investigator . 3 . Concomitant treatment another investigational agent participate trial . 18 . Chronic use , define &gt; 2 week corticosteroid agent &gt; = 20 mg/day prednisone equivalent , within 4 week prior first administration BI 836858 . 19 . Treatment immunomodulatory agent within 4 week prior first administration BI 836858 . 20 . Patient receive prior treatment CD33 antibody . 21 . In opinion Investigator patient unable unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>